MYOMO, INC.

MYOMO, INC. reported a revenue increase for the second quarter of 2026 to $11.70 million, up from $9.65 million year-over-year, and a reduced net loss of $(4.02) million compared to $(4.63) million in the prior year. Diluted EPS improved to $(0.09) from $(0.11) year-over-year. The company also significantly decreased cash used in operating activities for the first six months of 2026 to $(4.14) million from $(11.54) million in the same period last year, and stated it has sufficient liquidity to fund operations for at least the next twelve months.

Myomo, Inc. reported strong financial results for the second quarter ended June 30, 2026, with revenue reaching $11.7 million, a 21% increase year-over-year, exceeding expectations. The company demonstrated significant operating leverage, with gross margin expanding to 72.1% and Adjusted EBITDA loss improving by 79% to $0.8 million. Driven by the success of its go-to-market approach and growing clinical referral network, Myomo raised its full-year revenue guidance to $45 million to $47 million.

MYOMO, Inc. stockholders approved key proposals at the Annual Meeting on June 25, 2026. This included an amendment to the 2018 Stock Option and Incentive Plan, increasing available shares by 1,833,000, and an amendment to the Certificate of Incorporation to raise the authorized common stock to 100,000,000 shares. Stockholders also elected two Class III directors, ratified the independent auditor, and approved executive compensation in advisory votes.

Myomo, Inc. stockholders approved key proposals at the Annual Meeting on June 25, 2026. This included an amendment to the Certificate of Incorporation to increase the authorized common stock to 100,000,000 shares. Additionally, the Myomo 2018 Stock Option and Incentive Plan was amended to increase available shares by 1,833,000. Stockholders also re-elected Paul R. Gudonis and Thomas F. Kirk as directors, ratified CBIZ CPAs P.C. as the independent auditor, and approved executive compensation in an advisory vote.

Myomo, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 25, 2026. Key proposals include the election of two Class III directors, an increase of 1,833,000 shares for the 2018 Stock Option and Incentive Plan, and an amendment to increase authorized common stock to 100,000,000 shares. Stockholders will also vote on executive compensation, auditor ratification, and an advisory proposal on director classification.

Myomo, Inc. announced the appointment of Joseph M. Manko Jr. to its Board of Directors, effective May 9, 2026. Mr. Manko, who is the Senior Principal of Horton Capital Management LLC and a significant shareholder, brings over 25 years of experience in investment banking, private equity, and asset management. He will serve as a Class I director until the 2027 annual meeting and will be compensated similarly to other non-employee directors, including an annual cash retainer of $60,000 and an $85,000 annual RSU grant. This appointment expands Myomo's board to seven directors, with management expressing confidence in his ability to contribute to the company's growth strategy and shareholder value.

Myomo, Inc. reported a 2.9% increase in revenue to $10.1 million for Q1 2026, compared to $9.8 million in Q1 2025. The company's net loss narrowed significantly to $3.0 million, or $0.07 per share, from $3.5 million, or $0.08 per share, in the prior year. Operating cash outflow improved to $2.2 million from $2.7 million. The company believes its current cash and investments will fund operations for at least the next twelve months.

Myomo, Inc. reported first quarter 2026 financial results with revenue of $10.1 million, a 3% increase year-over-year. The company narrowed its net loss to $3.0 million, or $(0.07) per share, and improved Adjusted EBITDA by 20%. Key operational achievements include 49% of revenue from recurring patient sources and a 12% increase in MyoPro orders received, alongside expanded market access. The company provided Q2 2026 revenue guidance of $10.3 million to $10.8 million and reaffirmed full-year revenue guidance.

MYOMO, Inc. filed an Amendment No. 1 on Form 10-K/A to its Annual Report for the fiscal year ended December 31, 2025. The amendment primarily includes previously omitted Part III information, detailing directors, executive officers, corporate governance, and executive compensation. It also corrects typographical errors in officer certifications. William J. Febbo was appointed to the board of directors on April 14, 2026.

Myomo, Inc. filed an Amendment No. 1 to its 2025 Annual Report on Form 10-K to include previously omitted Part III information, correct certification dates, and provide updated certifications. The amendment details the company's directors, executive officers, corporate governance, and executive compensation. William J. Febbo was appointed to the board of directors on April 14, 2026. CEO Paul R. Gudonis's total compensation for 2025 was $1,201,183.